Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Biocon Ltd.
Industry Sector: HealthTechnology
CEO: Peter James Jonathan Bains; Siddharth Mittal, CPA
Number Of Employees: 16,315
Enterprise Value: $6,092,681,512
PE Ratio: 50.62
Exchange/Ticker 1: NSE:BIOCON
Exchange/Ticker 2: BSE:532523
Latest Market Cap: $4,757,593,599
BioCentury | Mar 15, 2025
Data Byte
VEGF ophthalmic sales: Vabysmo gains ground, biosimilars struggle to take off
Eylea remains market leader as Roche’s grows its share of AMD pie; biosimilars still a rounding error
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New I&I indications take center stage
Inflammation and immunology readouts to define new priority indications, modality opportunities in immune reset
BioCentury | Sep 13, 2024
Finance
Trio of first-day pops may bode well for biotech IPO window
With three biotechs trading up after NASDAQ debuts, sustained positive performance could further open window
BioCentury | Aug 26, 2024
Finance
Three’s a crowd? MBX follows Bicara, Zenas into IPO queue
Indiana-based developer of long-acting peptide therapeutics is latest mid-to-late-stage biotech to seek NASDAQ listing
BioCentury | Aug 24, 2024
Finance
Public Equity Report: Signs of life for biotech IPOs as Zenas, Bicara file, TYK sticks landing
Pair of well-funded late-stage biotechs seek NASDAQ listings, Shanghai cancer company prices deal in Hong Kong
BioCentury | May 31, 2024
Data Byte
FDA’s May approvals: an mRNA RSV vax, a bispecific and biosimilars
Moderna’s mResvia is its first mRNA vaccine approved outside COVID-19 pandemic
BioCentury | May 22, 2024
Market Access
What’s behind CVS’s changing adalimumab strategy
Company opens the door to biosimilars on its major formularies while partnering with AbbVie on a co-branded Humira
BioCentury | Dec 13, 2023
Finance
Dec. 12 Quick Takes: Targeted genomic DNA insertion company Tome launches with $213M
Plus: Bicara’s latest big round is a $165M series C, Shinobi launches, Pfizer readies to close Seagen deal and more
BioCentury | Sep 18, 2023
Management Tracks
Peter Bains named group CEO at Biocon
Plus: CEO changes at Lonza and Black Diamond, and updates from ImmunoGen, BenevolentAI and Nilogen
BioCentury | Aug 30, 2023
Politics, Policy & Law
IRA drug list underscores challenges for industry
Selections underline difficulty in predicting how Inflation Reduction Act will be implemented
Items per page:
1 - 10 of 296